AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma. Spender LC, Watt DM, Baxter MA, Shuttleworth MK, et al. Br J Cancer 2025;133:709-722.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Spender LC, Watt DM, Baxter MA, Shuttleworth MK, et al. AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma. Br J Cancer 2025;133:709-722.
PMID: 40615716